Dialogue's core digital services continued to
drive growth with more than $6.7
million in net new ARR, while the adjusted EBITDA loss
narrowed for a sixth consecutive quarter to less than $1 million
MONTREAL, Aug. 14,
2023 /CNW/ - Dialogue Health Technologies Inc.
(TSX: CARE) ("Dialogue" or the "Company"), Canada's premier health and wellness virtual
healthcare platform, announced today its financial and operational
results for the three and six months ended June 30, 2023. Financial references are in
Canadian dollars unless otherwise indicated.
"We delivered another strong performance during the second
quarter and are executing well on our plan to drive profitable
growth in the near future. We are well positioned to continue
winning market share across our services, signing more than
$6.7 million in net new ARR in our
core digital business, including several large enterprise
customers," said Cherif Habib, Chief Executive Officer of
Dialogue. "Importantly, we concluded a notable licensing
agreement with Sun Life in the United
States, providing us with new growth opportunities and
immediate scale in the world's largest addressable health and
wellness market. Furthermore, we are excited about the prospects of
joining forces with Sun Life, a company with whom we share a common
purpose of helping people live healthier lives, and expect to drive
continued innovation as we combine the strength of both
organizations."
Navaid Mansuri, Chief Financial
Officer, added: "We have continued to mature as an organization,
transitioning from a growth-at-all-cost mindset to one that focuses
on building a sustainable business for long-term success. We
realized further efficiencies in our member-facing operations and
reduced our operating expenses to 63% of revenue compared to nearly
76% at this time two years ago. As a result, we expanded our gross
margin once again and saw a sixth consecutive quarterly improvement
in adjusted EBITDA. We are well within reach of delivering our
first quarter of breakeven EBITDA by the end of 2023. Getting there
has been a key objective for our team and will provide Dialogue
with valuable flexibility to keep innovating and to support our
growth plans."
Q2 2023 Financial Highlights
(All capitalized terms
not defined herein, shall have the meaning and usefulness ascribed
to them in the Management's Discussion and Analysis ("MD&A")
for the three and six months ended June 30,
2023. Comparison periods in each case are the three and six
months ended June 30, 2022, unless
otherwise stated.)
Results presented below for the comparable period in 2022
reflect continuing operations only and exclude the Occupational
Health and Safety ("OHS") segment in Germany which was divested on December 31, 2022.
- Annual Recurring and Reoccurring Revenue ("ARR") from
continuing operations in the second quarter of 2023 grew 18.7%
year-over-year to $109.7 million,
driven by new Customer wins, by existing Customer and Partner
expansions, by price increases, and by the addition of Tictrac. The
increase was offset in part by previously disclosed churn at
Optima. Dialogue's core digital business in Canada, which represents 88% of total ARR,
maintained a strong momentum with growth of 36.7%
year-over-year.
- Revenue from continuing operations in the second quarter of
2023 increased by 17.2% year-over-year to $25.5 million. The improvement was driven mainly
by (i) organic growth in our core digital services due to a solid
increase in Members, (ii) an expansion of the Attach Rate as
existing Customers added more services, (iii) price increases, as
(iv) full quarter contribution from Tictrac. Overall growth was
offset in part by a revenue decline at Optima related to previously
disclosed churn.
- Members grew to just under 2.8 million in the second quarter of
2023, an increase of nearly 447,000 or 18.6%, year-over-year.
Excluding the contribution from Tictrac, Members grew 20.7%
year-over-year to approximately 2.6 million.
- Attach Rate grew to 1.57 in the second quarter of 2023 from
1.52 in the same period last year.
- Member-Service Units ("MSUs"), which we define as total Members
multiplied by the Attach Rate, rose 22.5% to 4.5 million in the
second quarter of 2023 from approximately 3.6 million in the same
period last year. Excluding the contribution from Tictrac, MSUs
grew 24.6% year-over-year to 4.2 million. This increase
demonstrates the success of Dialogue's land & expand strategy,
as both existing and new Customers continue to leverage our
integrated services.
- 38% of new direct Customers signed up for two services or more
in the second quarter of 2023. Combined with current Customer
expansions, the cumulative number of direct Members with two or
more services was 34% at the end of the second quarter of 2023,
compared to 24% at the same time last year.
- Rolling 12-month Net Retention Rate ("NRR") was 120% for the
second quarter of 2023 compared to 118% as of June 30, 2022. We did not experience any churn
within our direct mid-market and enterprise Customer segments in
the second quarter of 2023, compared to a churn of 782 Members in
the same period last year.
- Gross Margin from continuing operations increased to 59.7% in
the second quarter of 2023, compared to 48.7% in the same period
last year, as we realized efficiencies in our operations,
implemented price increases, continued to scale our Mental Health
service and Employee Assistance Program ("EAP"), and integrated
Tictrac's higher margin Wellness service.
- Adjusted EBITDA[1] loss from continuing operations was
$0.9 million in the second quarter of
2023 compared to a loss of $4.5
million in the same period last year. The smaller loss was
due to higher gross profit and strong cost control, partially
offset by inflationary cost increases across the business.
- Net loss from continuing operations was $5.8 million in the second quarter of 2023,
compared to $6.7 million in the same
period last year. The smaller loss was primarily due to higher
gross profit and interest income, offset in part by higher
operating expenses and a higher deferred income tax expense
compared to the second quarter of 2022.
- During the first quarter of 2023, we purchased $25.0 million in short-term guaranteed investment
certificates. Cash and cash equivalents and short-term investments
were $54.2 million as of June 30, 2023, compared to $62.7 million as of December 31, 2022. The decrease in the first six
months of the year was mainly the result of cash used in operations
and for working capital purposes, as well as the repayment of
long-term debt and lease liabilities.
____________________________
|
1
Adjusted EBITDA is a Non-IFRS financial measure. Refer to the
reconciliation contained in the Non-IFRS Financial Measures
section, beginning on page 3 of this earnings release.
|
Q2 2023 Key Business Developments and Subsequent Events
- We launched Dialogue's Well-Being Score, a monthly pulse to
help members proactively manage and improve their health and
well-being. The Well-Being Score is seamlessly incorporated into
Dialogue's Integrated Health PlatformTM, across all
programs, enhancing support and directing members towards the right
care, at the right time.
- We developed new nutrition-focused content and features,
expanding Dialogue's Wellness program even further. The new Eat
Well Healthy Habit Collection equips members with carefully
curated, clinically-vetted advice for building healthy nutrition
habits into their existing routine.
- We hosted Dialogue's 5th annual Think Tank, focused on
fostering resilience through employee well-being. The successful
event brought together senior leaders from various client
organizations and created a space for sharing expert experiences,
insights, and perspectives.
- For a fourth consecutive year, we have been certified as a
Great Place to WorkTM organization by Great Place to
Work® Canada. This
employee-validated recognition positions Dialogue well to get
noticed as an employer of choice and attract great talent, while
branding Dialogue as a company that cares and wins the attention
and loyalty of customers.
- On July 26, 2023, Dialogue
entered into a definitive agreement to be acquired by Sun Life
Financial Inc. ("Sun Life") for $5.15
in cash per common share. For more details about the transaction,
please consult our press release. In connection with and subject to
closing the transaction, Dialogue will apply to have its common
shares delisted from the TSX and will cease to be a reporting
issuer under Canadian securities laws.
Changes to the Board of Directors
Melissa Kennedy, Executive
Vice-President, Chief Legal Officer & Public Policy Officer at
Sun Life, stepped down from Dialogue's board of directors. The
Company does not intend to fill the vacancy left by Ms. Kennedy's
departure.
"It was a pleasure serving on Dialogue's board to further
their mission of helping Canadians improve their health and
well-being." said Ms. Kennedy. "The Company's recent announcement
regarding the proposed acquisition of Dialogue by Sun Life is an
important milestone and an exciting opportunity for both
organizations. In light of the upcoming transaction, it was an
appropriate time for me to step down from the board. Thank you to
our Chair, fellow board members and management team."
Notice of Conference Call
As a result of the announcement on July
26, 2023, that Dialogue has entered into a definitive
agreement to be acquired by Sun Life, the Company will not host a
conference call with analysts.
Non-IFRS ("International Financial Reporting Standards")
Financial Measures
This press release makes reference to certain non-IFRS measures,
such as "EBIT" (which stands for net profit or loss before
net profit or loss from discontinued operations, net financing
(income) expenses and income taxes), "EBITDA" (which stands
for net profit or loss before net loss from discontinued
operations, net financing (income) expenses, income taxes,
depreciation of property and equipment, amortization of intangible
assets and amortization of right-of-use assets) and
"Adjusted EBITDA" (which stands for net profit or
loss before net loss from discontinued operations, net financing
(income) expenses, income taxes, depreciation of property and
equipment, amortization of intangible assets, amortization of
right-of-use assets, disposal costs, acquisition costs,
restructuring costs, transaction costs, share-based payments
expense, change in contingent consideration, asset write-off and
impairment and foreign exchange gain or loss). This earnings
release also makes reference to Annual Recurring and Reocurring
Revenue ("ARR"), Net Retention Rate ("NRR"),
Member-Service Units ("MSUs"), Attach Rate and Members,
which are key performance indicators. The key performance
indicators used by the Company may be calculated in a manner
different than similar key performance indicators used by other
companies. These measures and key performance indicators are not
recognized under IFRS and do not have a standardized meaning
prescribed by IFRS and are therefore unlikely to be comparable to
similar measures presented by other companies. Rather, these
measures are provided as additional information to complement those
IFRS measures by providing further understanding of our results of
operations from management's perspective. Accordingly, these
measures should not be considered in isolation nor as a substitute
for analysis of our financial information as reported under IFRS.
We also believe that other users, such as securities analysts,
investors and other interested parties, frequently use non-IFRS
measures, particularly in the evaluation of issuers.
Management also uses non-IFRS measures in order to facilitate
operating performance comparisons from period to period, to prepare
annual operating budgets and forecasts and to determine components
of management compensation. Where applicable, we provide a clear
quantitative reconciliation from the non-IFRS financial measures to
the most directly comparable measure calculated in accordance with
IFRS.
The following table reconciles net loss to Adjusted EBITDA loss
for the three and six months ended June 30,
2023 and 2022:
DIALOGUE HEALTH TECHNOLOGIES
INC.
ADJUSTED EBITDA
FOR THE THREE AND SIX
MONTHS ENDED JUNE 30, 2023 and
2022
(in thousands of
CAD)
|
|
Three months
ended
June
30,
|
|
Six months
ended
June
30,
|
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
|
$
|
|
$
|
|
$
|
|
$
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
(5,757)
|
|
(8,387)
|
|
(8,412)
|
|
(15,454)
|
Net loss from
discontinued operations
|
|
—
|
|
1,648
|
|
—
|
|
2,037
|
Net financing
income
|
|
(518)
|
|
(169)
|
|
(1,020)
|
|
(194)
|
Current income tax
expense
|
|
17
|
|
25
|
|
23
|
|
48
|
Deferred income tax
expense (recovery)
|
|
920
|
|
(165)
|
|
920
|
|
(250)
|
EBIT
|
|
(5,338)
|
|
(7,048)
|
|
(8,489)
|
|
(13,813)
|
Depreciation of
property and equipment
|
|
186
|
|
244
|
|
344
|
|
381
|
Amortization of
intangible assets
|
|
491
|
|
472
|
|
979
|
|
841
|
Amortization of
right-of-use assets
|
|
107
|
|
160
|
|
214
|
|
267
|
EBITDA
|
|
(4,554)
|
|
(6,172)
|
|
(6,952)
|
|
(12,324)
|
Share-based payments
expense
|
|
1,231
|
|
954
|
|
2,091
|
|
1,522
|
Acquisition
costs
|
|
—
|
|
541
|
|
—
|
|
634
|
Change in contingent
consideration
|
|
201
|
|
43
|
|
(245)
|
|
134
|
Restructuring
costs
|
|
260
|
|
15
|
|
356
|
|
15
|
Disposal
costs
|
|
—
|
|
—
|
|
4
|
|
—
|
Transaction
costs
|
|
1,989
|
|
—
|
|
2,112
|
|
—
|
Foreign exchange loss
(gain)
|
|
21
|
|
165
|
|
(61)
|
|
165
|
Adjusted
EBITDA
|
|
(852)
|
|
(4,454)
|
|
(2,695)
|
|
(9,854)
|
About Dialogue
Incorporated in 2016, Dialogue is Canada's premier virtual healthcare and
wellness platform, providing affordable, on-demand access to
quality care. Through our team of health professionals, we serve
employers and organizations who have an interest in the health and
well-being of their employees, members and their families. Our
Integrated Health Platform™ is a one-stop healthcare hub that
centralizes all of our programs in a single, user-friendly
application, providing access to services 24 hours per day,
365 days per year from the convenience of a smartphone, computer or
tablet. Dialogue is the first virtual care provider to receive the
Accreditation Canada Primer award, a third-party validation of
safety and high-level quality of care.
Forward-Looking Information
This release includes "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
statements") within the meaning of applicable securities laws.
Forward-looking information may relate to our financial outlook
(including revenues and Adjusted EBITDA), and anticipated events or
results and may include information regarding our financial
position, business strategy, growth strategies, addressable
markets, budgets, operations, financial results, taxes, dividend
policy, plans and objectives.
In some cases, but not necessarily in all cases, forward-looking
statements can be identified by the use of forward-looking
terminology such as "plans" "targets", "expects" or "does not
expect", "is expected", "an opportunity exists", "is positioned",
"estimates", "intends", "assumes", "anticipates" or "does not
anticipate" or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might", "will" or "will be taken", "occur" or "be
achieved". In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances contain forward-looking statements. Forward-looking
statements are not historical facts, nor guarantees or assurances
of future performance but instead represent management's current
beliefs, expectations, estimates and projections regarding future
events and operating performance.
Forward-looking statements are necessarily based on a number of
opinions, assumptions and estimates that, while considered
reasonable by Dialogue as of the date of this release, are subject
to inherent uncertainties, risks and changes in circumstances that
may differ materially from those contemplated by the
forward-looking statements. Important factors that could cause
actual results to differ, possibly materially, from those indicated
by the forward-looking statements include, but are not limited to,
the risk factors identified under "Risk Factors" in the Company's
latest annual information form, and in other periodic filings that
the Company has made and may make in the future with the securities
commissions or similar regulatory authorities in Canada, all of which are available under the
Company's SEDAR+ profile at www.sedarplus.ca. These factors are not
intended to represent a complete list of the factors that could
affect Dialogue. However, such risk factors should be considered
carefully. There can be no assurance that such estimates and
assumptions will prove to be correct. You should not place undue
reliance on forward-looking statements, which speak only as of the
date of this release. Dialogue undertakes no obligation to publicly
update any forward-looking statement, except as required by
applicable securities laws.
Although we have attempted to identify important risk factors
that could cause actual results to differ materially from those
contained in forward-looking information, there may be other risk
factors not currently known to us or that we currently believe are
not material that could also cause actual results or future events
to differ materially from those expressed in such forward-looking
information. There can be no assurance that such information will
prove to be accurate, as actual results and future events could
differ materially from those anticipated in such information.
Accordingly, you should not place undue reliance on forward-looking
information. The forward-looking information represents our
expectations as of the date of this earnings release (or as the
date it is otherwise stated to be made) and is subject to change
after such date. However, we disclaim any intention or obligation
or undertaking to update or revise any forward-looking information
whether as a result of new information, future events or otherwise,
except as required under applicable Canadian securities laws. All
of the forward-looking information contained in this earnings
release is expressly qualified by the foregoing cautionary
statements.
DIALOGUE HEALTH TECHNOLOGIES INC.
INTERIM CONDENSED CONSOLIDATED STATEMENT OF
NET LOSS
FOR THE THREE AND SIX MONTHS ENDED JUNE
30, 2023 AND 2022
(in thousands of CAD
except share and per share data)
|
Three months
ended
June
30,
|
|
Six months
ended
June
30,
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
$
|
|
$
|
|
$
|
|
$
|
Continuing
operations
|
|
|
|
|
|
|
|
Revenue
|
25,539
|
|
21,791
|
|
50,071
|
|
41,328
|
Cost of
services
|
10,294
|
|
11,172
|
|
20,750
|
|
22,696
|
Gross profit
|
15,245
|
|
10,619
|
|
29,321
|
|
18,632
|
|
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
|
|
|
|
General and
administrative
|
11,630
|
|
11,228
|
|
20,433
|
|
19,400
|
Sales and
marketing
|
4,064
|
|
2,960
|
|
8,470
|
|
6,323
|
Product and
development
|
3,658
|
|
2,525
|
|
6,816
|
|
5,200
|
Share-based payments
expense
|
1,231
|
|
954
|
|
2,091
|
|
1,522
|
|
20,583
|
|
17,667
|
|
37,810
|
|
32,445
|
|
|
|
|
|
|
|
|
Operating loss from
continuing operations
|
(5,338)
|
|
(7,048)
|
|
(8,489)
|
|
(13,813)
|
|
|
|
|
|
|
|
|
Other
expenses
|
|
|
|
|
|
|
|
Net financing
income
|
(518)
|
|
(169)
|
|
(1,020)
|
|
(194)
|
|
(518)
|
|
(169)
|
|
(1,020)
|
|
(194)
|
|
|
|
|
|
|
|
|
Net loss before
income taxes from continuing operations
|
(4,820)
|
|
(6,879)
|
|
(7,469)
|
|
(13,619)
|
Current income tax
expense
|
17
|
|
25
|
|
23
|
|
48
|
Deferred income tax
expense (recovery)
|
920
|
|
(165)
|
|
920
|
|
(250)
|
Net loss from
continuing operations
|
(5,757)
|
|
(6,739)
|
|
(8,412)
|
|
(13,417)
|
Net loss from
discontinued operations
|
—
|
|
(1,648)
|
|
—
|
|
(2,037)
|
Net
loss
|
(5,757)
|
|
(8,387)
|
|
(8,412)
|
|
(15,454)
|
|
|
|
|
|
|
|
|
Loss from continuing
operations per share - basic and diluted
|
(0.09)
|
|
(0.10)
|
|
(0.13)
|
|
(0.20)
|
Loss from
discontinued operations per share - basic and
diluted
|
—
|
|
(0.02)
|
|
—
|
|
(0.03)
|
Loss per share -
basic and diluted
|
(0.09)
|
|
(0.12)
|
|
(0.13)
|
|
(0.23)
|
DIALOGUE HEALTH TECHNOLOGIES INC.
INTERIM CONDENSED CONSOLIDATED STATEMENT OF
OTHER COMPREHENSIVE LOSS
FOR THE THREE AND SIX MONTHS ENDED JUNE
30, 2023 AND 2022
(in thousands of
CAD)
|
Three months
ended
June
30,
|
|
Six months
ended
June
30,
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
$
|
|
$
|
|
$
|
|
$
|
Net loss from
continuing operations
|
(5,757)
|
|
(6,739)
|
|
(8,412)
|
|
(13,417)
|
Net loss from
discontinued operations
|
—
|
|
(1,648)
|
|
—
|
|
(2,037)
|
Net
loss
|
(5,757)
|
|
(8,387)
|
|
(8,412)
|
|
(15,454)
|
|
|
|
|
|
|
|
|
Other comprehensive
loss from continuing operations
|
|
|
|
|
|
|
|
Items that may be
reclassified subsequently to net loss from continuing
operations
|
|
|
|
|
|
|
Foreign currency
translation gain
|
(79)
|
(18)
|
|
(707)
|
|
(69)
|
|
|
|
|
|
|
|
|
Item that will not
be reclassified subsequently to net loss from continuing
operations
|
|
|
|
|
|
|
|
Changes in fair value
of investments recorded at fair value through other comprehensive
income
|
—
|
|
—
|
|
1,004
|
|
—
|
Comprehensive loss
from continuing operations
|
(5,678)
|
|
(6,721)
|
|
(8,709)
|
|
(13,348)
|
|
|
|
|
|
|
|
|
Other comprehensive
loss from discontinued operations
|
|
|
|
|
|
|
|
Foreign currency
translation gain
|
—
|
|
(236)
|
|
—
|
|
(544)
|
Comprehensive loss
from discontinued operations
|
—
|
|
(1,412)
|
|
—
|
|
(1,493)
|
|
|
|
|
|
|
|
|
Total comprehensive
loss
|
(5,678)
|
|
(8,133)
|
|
(8,709)
|
|
(14,841)
|
DIALOGUE HEALTH TECHNOLOGIES INC.
INTERIM CONDENSED CONSOLIDATED STATEMENT OF
FINANCIAL POSITION
AS AT JUNE 30, 2023 AND
DECEMBER 31, 2022
(in thousands of
CAD)
|
June
30,
|
|
December
31,
|
|
2023
|
|
2022
|
|
$
|
|
$
|
Assets
|
|
|
|
Current
assets
|
|
|
|
Cash and cash
equivalents
|
29,181
|
|
62,697
|
Short term
investments
|
25,000
|
|
—
|
Trade and other
receivables
|
19,571
|
|
17,190
|
Prepaid
expenses
|
3,631
|
|
2,443
|
|
77,383
|
|
82,330
|
|
|
|
|
Investment
|
—
|
|
1,004
|
Property and
equipment
|
787
|
|
936
|
Right-of-use
assets
|
570
|
|
784
|
Intangible
assets
|
5,358
|
|
6,237
|
Goodwill
|
24,978
|
|
24,586
|
Deferred income tax
asset
|
2,642
|
|
3,511
|
|
111,718
|
|
119,388
|
Liabilities
|
|
|
|
Current
liabilities
|
|
|
|
Trade payable and
accrued liabilities
|
16,933
|
|
16,724
|
Unearned
revenue
|
420
|
|
912
|
Current portion of
contingent consideration payable
|
1,701
|
|
1,425
|
Current portion of
long-term debt
|
400
|
|
400
|
Current portion of
lease liabilities
|
402
|
|
404
|
|
19,856
|
|
19,865
|
|
|
|
|
Non-current portion of
lease liabilities
|
109
|
|
343
|
Non-current portion of
long-term debt
|
474
|
|
707
|
Non-current portion of
contingent consideration payable
|
—
|
|
664
|
Deferred income tax
liability
|
422
|
|
458
|
|
20,861
|
|
22,037
|
|
|
|
|
Shareholders'
equity
|
|
|
|
Share
capital
|
462,028
|
|
459,962
|
Equity
reserve
|
6,261
|
|
6,112
|
Changes in fair value
of investments recorded at fair value through other comprehensive
income
|
(1,004)
|
|
—
|
Cumulative translation
adjustment
|
819
|
|
112
|
Deficit
|
(377,247)
|
|
(368,835)
|
|
90,857
|
|
97,351
|
|
111,718
|
|
119,388
|
|
|
|
|
DIALOGUE HEALTH TECHNOLOGIES INC.
INTERIM CONDENSED CONSOLIDATED STATEMENT OF
CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30,
2023 AND 2022
(in thousands of
CAD)
|
2023
|
|
2022
|
|
$
|
|
$
|
Operating
activities
|
|
|
|
Net loss
|
(8,412)
|
|
(15,454)
|
Items not affecting
cash
|
|
|
|
Increase (decrease) of
contingent consideration
|
(245)
|
|
134
|
Unrealized foreign
exchange gain
|
(61)
|
|
—
|
Deferred income tax
expense (recovery)
|
920
|
|
(250)
|
Depreciation of
property and equipment
|
344
|
|
404
|
Amortization of
right-of-use assets
|
214
|
|
351
|
Net financing
income
|
(1,020)
|
|
(194)
|
Amortization of
intangible assets
|
979
|
|
906
|
Share-based
payments
|
2,091
|
|
1,522
|
|
(5,190)
|
|
(12,581)
|
Net changes in non-cash
operating working capital items
|
|
|
|
Trade and other
receivables
|
(1,649)
|
|
(4,014)
|
Prepaid
expenses
|
(1,188)
|
|
(1,990)
|
Trade and other
payables
|
376
|
|
381
|
Unearned
revenue
|
(492)
|
|
691
|
|
(8,143)
|
|
(17,513)
|
Investing
activities
|
|
|
|
Purchase of property
and equipment
|
(194)
|
|
(419)
|
Purchase of intangible
assets
|
—
|
|
(1)
|
Short term
investments
|
(25,000)
|
|
—
|
Investment
|
—
|
|
(1,004)
|
Payment of Tictrac
Ltd. contingent consideration
|
(136)
|
|
—
|
Acquisition of Tictrac
Ltd. net of cash acquired
|
—
|
|
(24,253)
|
Interest income
received
|
376
|
|
222
|
|
(24,954)
|
|
(25,455)
|
Financing
activities
|
|
|
|
Performance share
units settled in cash
|
—
|
|
(172)
|
Options
exercised
|
180
|
|
92
|
Repayment of long-term
debt
|
(233)
|
|
(200)
|
Repayment of lease
liabilities
|
(252)
|
|
(512)
|
Interest
paid
|
(70)
|
|
(84)
|
|
(375)
|
|
(876)
|
Effect of foreign
currency translation
|
(44)
|
|
613
|
Net decrease in cash
and cash equivalents
|
(33,516)
|
|
(43,231)
|
Cash and cash
equivalents, beginning of the period
|
62,697
|
|
104,296
|
Cash and cash
equivalents, end of the period
|
29,181
|
|
61,065
|
SOURCE Dialogue Health Technologies Inc.